Posteroinferior myocardial infarction

Summary

Posteroinferior myocardial infarction (MONDO:0003670) is a disease. A subtype of myocardial infarction — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	posteroinferior myocardial infarction
Mondo ID	MONDO:0003670
DOID	DOID:5843
UMLS	C1142433
MedGen	216044
Is cancer (heuristic)	no

Also known as: posteroinferior myocardial infarction by ECG finding · posteroinferior myocardial infarction by EKG finding

Disease family

This is a subtype of myocardial infarction. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › cardiovascular disorder › heart disorder › myocardial disorder › myocardial infarction › posteroinferior myocardial infarction

Related subtypes (13): septal myocardial infarction, posterior myocardial infarction, apical myocardial infarction, subendocardial myocardial infarction, posterolateral myocardial infarction, inferolateral myocardial infarct, lateral myocardial infarction, silent myocardial infarction, anteroseptal myocardial infarction, acute myocardial infarction, myocardial stunning, anterolateral myocardial infarction, inferior myocardial infarction

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.